Article
Persistently elevated C-reactive protein level in the first year of antiretroviral therapy, despite virologic suppression, Is associated with HIV disease progression in resource-constrained settings
Registro en:
SHIVAKOTI, Rupak. et al. Persistently elevated C-reactive protein level in the first year of antiretroviral therapy, despite virologic suppression, Is associated With HIV disease progression in resource-constrained settings. The Journal of Infectious Diseases, v. 213, n. 7, p. 1074–1078, 2016.
0022-1899
10.1093/infdis/jiv573
Autor
Shivakoti, Rupak
Yang, Wei-Teng
Berendes, Sima
Mwelase, Noluthando
Kanyama, Cecilia
Pillay, Sandy
Samaneka, Wadzanai
Santos, Breno
Poongulali, Selvamuthu
Tripathy, Srikanth
Riviere, Cynthia
Lama, Javier R.
Cardoso, Sandra W.
Sugandhavesa, Patcharaphan
Balagopal, Ashwin
Gupte, Nikhil
Semba, Richard D.
Campbell, Thomas B.
Bollinger, Robert C.
Gupta, Amita
NWCS 319 and PEARLS Study Team
Resumen
A case-cohort analysis of human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (ART) was performed within a multicountry randomized trial (PEARLS) to assess the prevalence of persistently elevated C-reactive protein (CRP) levels, based on serial measurements of CRP levels, and their association with HIV clinical failure. A persistently elevated CRP level in plasma (defined as ≥ 5 mg/L at both baseline and 24 weeks after ART initiation) was observed in 50 of 205 individuals (24%). A persistently elevated CRP level but not an elevated CRP level only at a single time point was independently associated with increased clinical failure, compared with a persistently low CRP level, despite achievement of virologic suppression. Serial monitoring of CRP levels could identify individuals who are at highest risk of HIV progression and may benefit from future adjunct antiinflammatory therapies. 2028-08-30